Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Engineered Organoids in Oral and Maxillofacial Regeneration

[iScience] The authors summarize the recent progress of novel approaches to engineering oral and maxillofacial organoids. They introduce the necessary components and their roles in forming oral and maxillofacial organoids.

Microglia-Containing Human Brain Organoids for the Study of Brain Development and Pathology

[Molecular Psychiatry] Scientists review the current methods used to generate microglia-containing human brain organoids (MC-HBOs) and provide opinions on the use of MC-HBOs for disease modeling and functional studies.

Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents

[ERS Genomics Limited] Crown Bioscience, Inc. and ERS Genomics Ltd. have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CRISPR/Cas9 for gene editing.

Performance Assessment and Economic Analysis of a Human Liver-Chip for Predictive Toxicology

[Communications Medicine] 870 Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules identified as benchmarks by the Innovation and Quality consortium, who has published guidelines defining criteria for qualifying preclinical models.

Heterogeneous Matrix Stiffness Regulates the Cancer Stem-Like Cell Phenotype in Hepatocellular Carcinoma

[Journal of Translational Medicine] Investigators provided new insights into the interaction between matrix stiffness, cancer cell stemness, and heterogeneity, while also providing a novel hepatocellular carcinoma therapeutic strategy.

Dopamine Receptor D3 Is Related to Prognosis in Human Hepatocellular Carcinoma and Inhibits Tumor Growth

[BMC Cancer] Cell growth was tested by CCK8 assay, and Transwell assays were performed to assess cancer cell migration and invasion. The cAMP/ERK/CREB signaling pathway was evaluated by Western blot analysis and ELISA.

The Expression Characteristics and Clinical Significance of ACP6, a Potential Target of Nitidine Chloride, in Hepatocellular Carcinoma

[BMC Cancer] Researchers appraised the clinico-pathological significance of ACP6 in HCC via organizing expression profiles from globally multi-center microarrays and RNA-seq datasets. The molecular basis of ACP6 in HCC was explored through multidimensional analysis.

Dialysis Based-Culture Medium Conditioning Improved the Generation of Human Induced Pluripotent Stem Cell Derived-Liver Organoid in a High Cell Density

[Scientific Reports] Investigators developed a simple dialysis-based medium conditioning that fully utilized growth factors accumulation to improve hepatic differentiation of human iPSCs at a high cell density.

GL-V9 Alleviates Liver Fibrosis via Triggering GATA4-Mediated Senescence in Activated Hepatic Stellate Cells

[British Journal of Pharmacology] Bile duct ligation and carbon tetrachloride challenge were used to assess anti-fibrotic effects of GL-V9 in vivo. Mouse primary hepatic stellate cells and human HSC line LX2 also served as an in vitro liver fibrosis model.

Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

[Shanghai Junshi Biosciences Co., Ltd] Shanghai Junshi Biosciences Co., Ltd announced that the company has submitted a marketing authorization application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency for toripalimab

SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes

[Gut and Liver] Investigators provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with chronic liver disease (CLD), and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.

Pyxis Oncology Announces FDA Clearance of Two IND Applications

[Pyxis Oncology, Inc.] Pyxis Oncology, Inc. announced that it has received clearance for its two Investigational New Drug (IND) applications from the US FDA to initiate Phase I clinical trials.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!

spot_img